Over 900,000 COVID-19 Therapeutics Allocated This Week

The U.S. Department of Health and Human Services Administration for Strategic Preparedness and Response (ASPR) today announced its expanded allocations of U.S. FDA-authorized COVID-19 therapeutics, oral antiviral, and monoclonal antibodies (mAbs).

Since December 2021, ASPR has distributed about 9,975,306 COVID-19 therapeutics. 

On August 1, 2022, ASPR confirmed state and territorial health departments would receive 938,108 products this week:

Oral antivirals: Paxlovid (612,260) and Lagevrio (92,328).

mAbs: Evusheld (203,760) and Bebtelovimab (29,760).

At the state level, California will receive the largest allocation (42,035), followed by Texas, Florida, and New York.

ASPR says: 'State and territorial health department officials can request additional products at any time if a jurisdiction's current supply is insufficient to meet demand.'

To expand access, the U.S. government launched the 'Test to Treat' initiative in March 2022.

Through this program, people can get tested and – if they are positive and treatments are appropriate for them – receive a prescription from a healthcare provider (either on-site or through telehealth) and have their prescription filled all at one location.

These "One-Stop Test to Treat" sites are available at locations nationwide, including pharmacy-based clinics.

Note: The ASPR information was manually curated for mobile readership.